CA
AMLX icon

Cliff Asness’s Amylyx Pharmaceuticals AMLX Stock Holding History

Cliff Asness’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$374K Sell
20,819
-8,270
-28% -$128K ﹤0.01% 3524
2026
Q1 		$404K Buy
29,089
+1,242
+4% +$17.5K ﹤0.01% 3245
2025
Q4 		$336K Sell
27,847
-45,793
-62% -$622K ﹤0.01% 3120
2025
Q3 		$1M Buy
+73,640
New +$693K ﹤0.01% 2433
2025
Q1 		– Sell
-188,386
Closed -$712K – 3153
2024
Q4 		$712K Sell
188,386
-460,693
-71% -$2.17M ﹤0.01% 2071
2024
Q3 		$2.1M Sell
649,079
-2,691,864
-81% -$6.05M ﹤0.01% 1482
2024
Q2 		$6.35M Buy
3,340,943
+3,224,454
+2,768% +$6.25M 0.01% 923
2024
Q1 		$331K Buy
116,489
+93,145
+399% +$1.22M ﹤0.01% 2100
2023
Q4 		$344K Sell
23,344
-295
-1% -$4.52K ﹤0.01% 2020
2023
Q3 		$433K Buy
23,639
+9,408
+66% +$199K ﹤0.01% 1896
2023
Q2 		$307K Buy
14,231
+6,384
+81% +$172K ﹤0.01% 1930
2023
Q1 		$230K Buy
+7,847
New +$273K ﹤0.01% 2017

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Cliff Asness's AMLX Position: Q2 2026 in Review

Cliff Asness reduced its Amylyx Pharmaceuticals (AMLX) stake by 28% in Q2 2026, selling an estimated $128K and leaving 20,819 shares worth $374K. The position accounts for ﹤0.01% of the portfolio, ranked #3524.

Cliff Asness first reported a position in AMLX in Q1 2023 and has held it in 12 quarters since. The position peaked at $6.35M in Q2 2024. 205 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Cliff Asness held 20,819 shares of Amylyx Pharmaceuticals worth $374K as of Q2 2026.
  • Cliff Asness sold 8,270 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $128K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #3524 holding.
  • Cliff Asness first reported a position in Amylyx Pharmaceuticals in Q1 2023 and has held it in 12 quarters since.
  • Cliff Asness's Amylyx Pharmaceuticals position peaked at $6.35M in Q2 2024.
  • 205 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.